GHK‑Cu: the copper tripeptide in skin and wound-healing research

Few peptides studied in regenerative research are as small as GHK. It has only three amino acids: glycine, histidine and lysine. Bound to a copper ion, as GHK-Cu, it has been investigated for more than fifty years in contexts ranging from liver cell culture to diabetic foot ulcers and cosmetic skin care. This article reviews the main lines of evidence and draws a clear line between what has been measured in cells, in animals and in people.

A discovery in liver cell culture

The story begins in 1973, with a report that a synthetic tripeptide increased the survival of normal liver cells in culture and stimulated the growth of hepatoma cells^[1]. The peptide was later characterised as glycyl-L-histidyl-L-lysine, a component of human plasma.

GHK binds copper(II) ions with an affinity similar to that of the copper-transport site on albumin, forming the GHK-Cu complex^[2]. Its presence in plasma, saliva and urine, and a reported decline in plasma concentration with age, have made it a subject of interest in research on tissue ageing^[3].

Collagen and the extracellular matrix

The most direct laboratory evidence concerns collagen. In a 1988 study, GHK-Cu stimulated collagen synthesis in cultured fibroblasts. The effect began at extremely low concentrations, between 10⁻¹² and 10⁻¹¹ mol/L, peaked at about 10⁻⁹ mol/L, and did not depend on an increase in cell number^[4]. The authors noted that the GHK sequence occurs within the α2 chain of type I collagen, and suggested that the tripeptide might be released by proteases at a wound site and act locally.

Repair is not only about making new matrix; damaged matrix also has to be removed and remodelled. In a rat model using wound chambers implanted under the skin, GHK-Cu modulated the expression and activation of matrix metalloproteinases, the enzymes that break down and reshape connective tissue, with effects on the gelatinases MMP-2 and MMP-9^[5]. Reviews describe GHK as influencing both the synthesis and the breakdown of collagen and glycosaminoglycans, and the balance between metalloproteinases and their inhibitors^[3].

Wound healing: animal and human evidence

Reviews report accelerated healing with GHK-Cu in wound models across several species, including rats, mice and pigs^[3]. These studies establish plausibility, but they vary widely in design.

The most important human study is a multicentre, randomised, evaluator-blinded, placebo-controlled trial published in 1994. Patients with diabetic neuropathic foot ulcers received a standardised care programme of debridement, pressure-relieving footwear and education, plus either a topical GHK-Cu gel or a vehicle gel^[6].

The investigators also reported that closure was about three times faster with the active gel, and that benefit depended on starting treatment immediately after the initial debridement^[6].

What a modern replication would need

Diabetic foot ulcer research has become considerably more demanding since the 1994 trial. A contemporary study would typically pre-register its protocol and primary outcome, and use complete wound closure confirmed at a follow-up visit as the main endpoint rather than percentage area reduction. It would also report how many randomised patients were analysed and how missing data were handled, and blind not only the evaluators but also the people preparing and applying the gels. It would need enough participants to detect a clinically meaningful difference. These are not criticisms of the original investigators, who worked to the standards of their time. They explain why a single positive result from that era cannot, on its own, settle the question.

It is also worth separating two claims that are often blurred. The trial tested a specific topical gel within an intensive standard-care programme. It says nothing about GHK-Cu given by other routes, at other concentrations or for other purposes.

Gene expression and data mining

Some of the broadest claims about GHK come from gene-expression research. In a 2012 study, researchers profiled lung tissue from patients with chronic obstructive pulmonary disease and identified 127 genes whose expression tracked the severity of emphysema. Genes involved in tissue repair, including the TGF-β pathway, fell as destruction increased. Using the Connectivity Map, a database of gene-expression responses to thousands of compounds, they identified GHK as a compound able to reverse this signature. In cultured human fibroblasts, GHK reproduced TGF-β-like expression patterns and organised the actin cytoskeleton, and it restored collagen contraction and remodelling by fibroblasts taken from lungs affected by COPD^[7].

Subsequent reviews have drawn on similar data mining to state that GHK can shift the expression of several thousand human genes^[3][8]. These analyses are a legitimate way to generate hypotheses. They rely on expression changes measured in cultured cell lines, however, and do not show that the same changes occur in human tissue, or that they produce clinical benefit.

Cosmetic research

Much public interest in GHK-Cu comes from skin care. Reviews summarise controlled studies on aged skin reporting improvements in firmness, elasticity, fine lines and hyperpigmentation^[2]. Among the sources examined for this article, these cosmetic studies are described in reviews rather than reported as full peer-reviewed trials, which makes them difficult to assess independently.

Readers should also note the source of many overviews. The most comprehensive reviews of GHK are written by its original discoverer and colleagues, who list their affiliation as the research and development department of Skin Biology rather than an academic institution^[3][8]. Their expertise is considerable. Independent reviews and trials are still needed to balance the picture.

Broader proposed roles

The same research group has proposed roles for GHK beyond skin, including protection against oxidative stress, anti-inflammatory activity and potential relevance to age-related cognitive decline^[9]. These proposals draw together laboratory observations and gene-expression data, and are presented by their authors as hypotheses for further study.

Where the evidence stands

Summary

GHK-Cu is a naturally occurring copper-binding tripeptide with a coherent body of laboratory evidence on collagen synthesis and matrix remodelling, and one encouraging controlled trial in diabetic foot ulcers. Wider claims about gene regulation and systemic rejuvenation rest largely on data mining and on reviews written outside academic institutions. The most useful next steps would be independent, adequately powered trials with clearly defined clinical outcomes.